Blocking a pro-inflammatory lipid in brain tumor microenvironments could restore NK and T cell function.

Blocking a pro-inflammatory lipid in brain tumor microenvironments could restore NK and T cell function.

Glioblastoma (GBM) remains one of the deadliest cancers with only 15-month median survival. Its immunosuppressive tumor microenvironment—shaped partly by prostaglandin E2 (PGE2) produced via the COX-2 pathway—severely limits immunotherapy efficacy.

This review details how PGE2 acting through EP2 and EP4 receptors elevates cAMP, which downregulates NK cell activating receptors, exhausts CD8+ T cells, and expands regulatory T cells. The COX-2/PGE2 axis also mediates resistance to checkpoint inhibitors and CAR-T therapy.

Combining PGE2 inhibition with CAR-NK or CAR-T approaches could restore immune function and sensitize GBM to immunotherapy—a compelling research direction.

Key Findings

• PGE2 via COX-2 is a key driver of immunosuppression in GBM tumor microenvironment
• PGE2 downregulates NK cell activating receptors (NKG2D, NKp30) and induces CD8+ T cell exhaustion
• COX-2/PGE2 axis mediates resistance to checkpoint inhibitors and CAR-T therapy
• EP2/EP4 receptor blockade could restore NK and T cell function
• Combining PGE2 modulation with CAR-NK/CAR-T platforms holds promise for GBM

Implications

The COX-2/PGE2 axis is a rational co-target for combination immunotherapy in GBM. NSAIDs, COX-2 inhibitors, or EP receptor antagonists combined with CAR-T or checkpoint inhibitors could overcome immunosuppression in this otherwise refractory cancer.

Caveats

Review article; abstract-only. No new clinical or preclinical data. Most evidence from preclinical models. PGE2's dual role (intracellular pro-apoptotic vs. extracellular pro-tumorigenic) complicates therapeutic targeting. Clinical trials are limited.

Source: Cancer immunology, immunotherapy : CII — 2026-04-10